Abstract:This study examines the pivotal role of the PD‐1/PD‐L1 immune checkpoint interaction in tumor immunotherapy. Due to the absence of mature small molecule inhibitors in the market, exploring novel PD‐L1 small molecule inhibitors is imperative. Utilizing asymmetric biphenyl compounds developed by BMS Corporation, we assembled 39 small molecule compounds with analogous biphenyl scaffolds from the literature. By employing QSAR methods, these compounds were randomly divided into training and test sets, facilitating the successful construction of CoMFA and CoMSIA models, and thereby laying the groundwork for further research. Extracting insights from the spatial fields depicted in the three‐dimensional contour maps, including the electrostatic field, hydrophobic field, and hydrogen bond donor field, the most active molecule, 37, was selected from the training set. Its specific positions were modified, and functional groups were added to enhance its activity. Based on this, a series of structurally novel and potentially active small molecule compounds (37 a–37 e) were designed. Comprehensive studies were conducted on one of these compounds, 37 c, including molecular docking, molecular dynamics simulations, ADME predictions, and other operations, confirming its closer interaction with the amino acid residues of the PD‐L1 dimer in comparison to 37. This study offers new insights and options for the development of PD‐L1‐based small molecule inhibitors through the application of computational techniques and rational drug design principles. Blocking the interaction between programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) is a crucial immunotherapeutic strategy for cancer. Currently, all inhibitors available on the market that target PD‐1/PD‐L1 are monoclonal antibodies, with no small molecule drugs yet accessible. This study focused on PD‐L1 and conducted three‐dimensional quantitative structure‐activity relationship (3D‐QSAR) research on 39 PD‐L1 inhibitors using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). The CoMFA (q2=0.593, r2=0.991) and CoMSIA (q2=0.542, r2=0.971) models were successfully established. Based on these models, a series of structurally novel and potentially active PD‐L1 inhibitors (37 a–37 e) were designed. Among these compounds, 37 c exhibited superior performance, with CoMFA predicting a pIC50 value of 9.204 and CoMSIA predicting a pIC50 value of 8.597. Further molecular docking and molecular dynamics simulations revealed that compound 37 c establishes hydrophobic interactions with BTyr56 and BVal68 of PD‐L1, engages in hydrogen bonds with AAsp122, ALys124, and BTyr123, and forms electrostatic interactions with ALys124 and AMet115. The design of this biphenyl series of inhibitors offers additional options for the development of small molecule inhibitors targeting PD‐L1, with 37 c expected to be a promising inhibitor of PD‐L1.

Molecular electrostatic potential and volume-aided drug design based on an isoindolinone-containing cyclopeptide S-PK6

DFT-aided infrared and electronic circular dichroism spectroscopic study of cyclopeptide S-PK6 and the exploration of its antitumor potential by molecular docking

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Computational modeling of cyclic peptide inhibitor–MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations

Structure-Based Inhibitor Design for the Intrinsically Disordered Protein C-Myc

An experimental and computational investigation of the cyclopentene-containing peptide-derived compounds: focus on pseudo-cyclic motifs via intramolecular interactions

Cyclic Peptide Linker Design and Optimization by Molecular Dynamics Simulations

Design of Biphenyl‐Type Programmed Cell Death‐Ligand 1 Inhibitors Using 3D‐QSAR, Molecular Docking, and Molecular Dynamics Simulation

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

A Bionic‐Homodimerization Strategy for Optimizing Modulators of Protein–Protein Interactions: from Statistical Mechanics Theory to Potential Clinical Translation

A computational analysis of interaction mechanisms of peptide and non-peptide inhibitors with MDMX based on molecular dynamics simulation

Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo

A High-Resolution Structural Characterization and Physicochemical Study of How a Peptoid Binds to an Oncoprotein MDM2

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX.

DexDesign: A new OSPREY-based algorithm for designing D-peptide inhibitors

Insight into Interaction Mechanism of the Inhibitor Pdi6w with MDM2 Based on Molecular Dynamics

Systematic Mutational Analysis of Peptide Inhibition of the P53-Mdm2/Mdmx Interactions

Investigation of the MDM2-binding potential of de novo designed peptides using enhanced sampling simulations

Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning

Molecular modeling studies of Indoline Scaffold derivatives as PD‐1/PD‐L1 pathway inhibitors by QSAR, molecular docking and molecular dynamics simulation techniques